Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease : A 12-month follow-up study with paired liver biopsies. / Pedersen, Julie Steen; Rygg, Marte Opseth; Serizawa, Reza Rafiolsadat; Kristiansen, Viggo Bjerregaard; Wewer Albrechtsen, Nicolai J.; Gluud, Lise Lotte; Madsbad, Sten; Bendtsen, Flemming.

In: Journal of Clinical Medicine, Vol. 10, No. 17, 3783, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Pedersen, JS, Rygg, MO, Serizawa, RR, Kristiansen, VB, Wewer Albrechtsen, NJ, Gluud, LL, Madsbad, S & Bendtsen, F 2021, 'Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies', Journal of Clinical Medicine, vol. 10, no. 17, 3783. https://doi.org/10.3390/jcm10173783

APA

Pedersen, J. S., Rygg, M. O., Serizawa, R. R., Kristiansen, V. B., Wewer Albrechtsen, N. J., Gluud, L. L., Madsbad, S., & Bendtsen, F. (2021). Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies. Journal of Clinical Medicine, 10(17), [3783]. https://doi.org/10.3390/jcm10173783

Vancouver

Pedersen JS, Rygg MO, Serizawa RR, Kristiansen VB, Wewer Albrechtsen NJ, Gluud LL et al. Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies. Journal of Clinical Medicine. 2021;10(17). 3783. https://doi.org/10.3390/jcm10173783

Author

Pedersen, Julie Steen ; Rygg, Marte Opseth ; Serizawa, Reza Rafiolsadat ; Kristiansen, Viggo Bjerregaard ; Wewer Albrechtsen, Nicolai J. ; Gluud, Lise Lotte ; Madsbad, Sten ; Bendtsen, Flemming. / Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease : A 12-month follow-up study with paired liver biopsies. In: Journal of Clinical Medicine. 2021 ; Vol. 10, No. 17.

Bibtex

@article{d1b711bb262944d28a30836d2de0cea7,
title = "Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies",
abstract = "Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histologi-cal assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Conse-quently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p <0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.",
keywords = "Bariatric surgery, Liver histology, Non-alcoholic fatty liver disease, Non-alcoholic fatty liver disease activity score, Roux-en-Y gastric bypass, Sleeve gastrectomy",
author = "Pedersen, {Julie Steen} and Rygg, {Marte Opseth} and Serizawa, {Reza Rafiolsadat} and Kristiansen, {Viggo Bjerregaard} and {Wewer Albrechtsen}, {Nicolai J.} and Gluud, {Lise Lotte} and Sten Madsbad and Flemming Bendtsen",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Li-censee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/jcm10173783",
language = "English",
volume = "10",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "17",

}

RIS

TY - JOUR

T1 - Effects of roux-en-y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease

T2 - A 12-month follow-up study with paired liver biopsies

AU - Pedersen, Julie Steen

AU - Rygg, Marte Opseth

AU - Serizawa, Reza Rafiolsadat

AU - Kristiansen, Viggo Bjerregaard

AU - Wewer Albrechtsen, Nicolai J.

AU - Gluud, Lise Lotte

AU - Madsbad, Sten

AU - Bendtsen, Flemming

N1 - Publisher Copyright: © 2021 by the authors. Li-censee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histologi-cal assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Conse-quently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p <0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.

AB - Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histologi-cal assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Conse-quently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p <0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.

KW - Bariatric surgery

KW - Liver histology

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic fatty liver disease activity score

KW - Roux-en-Y gastric bypass

KW - Sleeve gastrectomy

U2 - 10.3390/jcm10173783

DO - 10.3390/jcm10173783

M3 - Journal article

C2 - 34501231

AN - SCOPUS:85113325713

VL - 10

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 17

M1 - 3783

ER -

ID: 280064295